TickerFacts.

Upstream Bio, Inc. (UPB): Cash & Equivalents

Annual figures by period end, from SEC filings.

$101.58M
As of 2025-12-31
$79.40M
As of 2026-06-30
$325.89M2023-12-31: $25.83M2024-12-31: $325.89M2025-12-31: $101.58M$101.58M
2023-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$101.58M-68.8%2026-03-26, Balance as of period end
2024-12-31$325.89Mn/m2026-03-26, Balance as of period end
2023-12-31$25.83Mn/a2025-03-12, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Upstream Bio, Inc. (UPB)2025-12-31$101.58M-68.8%
Cartesian Therapeutics, Inc. (RNAC)2025-12-31$125.14M-41.1%
TherapeuticsMD, Inc. (TXMD)2024-12-31$5.06M+16.9%
GeoVax Labs, Inc. (GOVX)2025-12-31$3.09M-44.0%
Camp4 Therapeutics Corp (CAMP)2025-12-31$109.52M+71.0%
Marker Therapeutics, Inc. (MRKR)2025-12-31$16.07M-16.3%
Korsana Biosciences, Inc. (KRSA)2025-12-31$3.24M+0.2%
Dianthus Therapeutics, Inc. (DNTH)2025-12-31$51.09M+124.1%
CervoMed Inc. (CRVO)2025-12-31$8.24M-8.5%

Compare UPB, RNAC, TXMD, GOVX side by side · Screen every company in Pharmaceutical Preparations ↗